Zevra Therapeutics
ZVRA
11.08
+0.35
+3.26%
Zevra Therapeutics
US · ZVRA
#3562 by market cap
11.08
+0.35
+3.26%
Live - 5344 symbols - heartbeat 324s ago
· 2026-10-08 09:19
Pre-market
11.07
-0.09%
After-hours
11.19
+0.99%
- Market cap
- 657.97M
- P/E (TTM)i
- 11.91
- P/Bi
- 3.02
- EPSi
- 1.35
- Div yieldi
- 0.00%
- 52W posi
- 44%
Reader sentiment
Are you bullish or bearish on ZVRA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.06, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +350.91% YoY
Margins
- Gross margin
- 84.52%
- Operating margin
- -3.98%
- Net margin
- 78.17%
Key ratios & quality
- Enterprise valuei
- 529.31M
- Altman Z-Scorei
- 2.06
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 12.84M | 13.29M | 28.65M | 10.16M | 27.46M | 23.61M | 106.47M |
| Gross profit | 0 | 9.89M | 11.98M | 26.59M | 9.94M | 25.29M | 16.20M | 89.99M |
| Selling & admin expenses | 12.51M | 10.82M | 7.92M | 8.70M | 15.04M | 34.31M | 54.87M | 77.62M |
| Research & development | 41.76M | 19.42M | 8.84M | 10.16M | 19.80M | 39.81M | 42.10M | 12.74M |
| Operating profit | -54.27M | -20.34M | -4.78M | 7.73M | -24.90M | -49.60M | -87.00M | -4.23M |
| Pretax profit | -56.59M | -24.54M | -12.79M | -8.52M | -26.81M | -46.05M | -90.14M | 86.68M |
| Tax | -126.00K | -22.00K | -34.00K | 34.00K | -33.00K | 0 | 15.37M | 3.45M |
| Net profit | -56.47M | -24.52M | -12.76M | -8.56M | -26.77M | -46.05M | -105.51M | 83.23M |
| Basic EPS | -50 | -13 | -3 | -2 | -1 | -1 | -2 | 1 |
| Diluted EPS | -50.40 | -13.23 | -3.21 | -2.11 | -0.78 | -1.30 | -2.28 | 1.35 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 20.40M | 25.88M | 26.06M | 34.13M | 36.22M | 39.66M |
| Gross profit | 19.06M | 13.50M | 24.83M | 32.61M | 34.32M | 38.14M |
| Selling & admin expenses | 19.55M | 20.78M | 16.94M | 20.35M | 20.78M | 16.56M |
| Research & development | 3.26M | 3.43M | 3.43M | 2.62M | 4.39M | 4.49M |
| Operating profit | -5.36M | -12.33M | 4.14M | 9.32M | 8.83M | 16.78M |
| Pretax profit | -1.92M | 76.91M | -977.00K | 12.67M | 44.80M | 12.79M |
| Tax | 1.18M | 2.20M | -433.00K | 501.00K | 6.91M | 4.04M |
| Net profit | -3.10M | 74.71M | -544.00K | 12.17M | 37.89M | 8.75M |
| Basic EPS | 0 | 1 | 0 | 0 | 1 | 0 |
| Diluted EPS | -0.06 | 1.21 | -0.01 | 0.19 | 0.60 | 0.14 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 23.72M | 6.97M | 8.38M | 115.06M | 92.83M | 86.94M | 86.03M | 223.01M |
| Cash & ST investments | 21.67M | 3.22M | 4.21M | 112.35M | 82.85M | 67.74M | 69.50M | 191.01M |
| Inventory | -- | -- | -- | -- | -- | 0 | 1.97M | 1.74M |
| Total assets | 26.75M | 10.51M | 11.21M | 132.94M | 115.34M | 172.33M | 178.13M | 284.73M |
| Total current liabilities | 12.00M | 5.43M | 7.54M | 4.23M | 12.02M | 73.72M | 34.07M | 39.28M |
| Short-term debt | 3.55M | 284.00K | 889.00K | 371.00K | 480.00K | 38.24M | 420.00K | 419.00K |
| Long-term debt | 78.11M | 77.34M | 68.05M | -- | 12.80M | 5.07M | 59.50M | 61.93M |
| Total liabilities | 93,312,000.00 | 84,963,000.00 | 77,621,000.00 | 5,823,000.00 | 40,220,000.00 | 110,463,000.00 | 138,461,000.00 | 130,074,000.00 |
| Total equity | -66.57M | -74.46M | -66.41M | 127.12M | 75.12M | 61.86M | 39.67M | 154.66M |
| Retained earnings | -221.19M | -245.71M | -258.47M | -267.03M | -353.73M | -399.78M | -505.29M | -422.06M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 81.57M | 226.34M | 225.12M | 223.01M | 229.97M | 251.30M |
| Cash & ST investments | 62.63M | 202.61M | 199.51M | 191.01M | 200.62M | 221.57M |
| Inventory | 2.56M | 1.11M | 1.37M | 1.74M | 2.31M | 2.45M |
| Total assets | 172.71M | 256.28M | 270.12M | 284.73M | 278.58M | 302.71M |
| Total current liabilities | 26.98M | 28.83M | 26.11M | 39.28M | 47.03M | 48.63M |
| Short-term debt | 589.00K | 525.00K | 441.00K | 419.00K | 406.00K | 626.00K |
| Long-term debt | 60.09M | 60.69M | 61.31M | 61.93M | -- | -- |
| Total liabilities | 131,685,000.00 | 139,047,000.00 | 136,951,000.00 | 130,074,000.00 | 72,775,000.00 | 85,060,000.00 |
| Total equity | 41.02M | 117.23M | 133.17M | 154.66M | 205.80M | 217.65M |
| Retained earnings | -508.39M | -433.68M | -434.23M | -422.06M | -384.17M | -375.42M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -54.20M | -23.74M | -1.94M | 10.44M | -18.72M | -33.54M | -69.67M | -1.60M |
| Depreciation & amortization | 324.00K | 304.00K | 273.00K | 257.00K | 944.00K | 1.01M | 6.39M | 4.05M |
| Free cash flow | -54.22M | -23.76M | -1.97M | 10.34M | -18.81M | -33.83M | -69.67M | -2.43M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 28.33M | -- | 0 | 46.47M | -4.72M | 2.66M | 64.52M | 8.64M |
| Ending cash balance | 19.12M | 3.56M | 4.32M | 112.35M | 65.47M | 43.05M | 33.79M | 62.41M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -8.22M | -3.60M | 4.71M | 5.52M | 6.14M | 17.03M |
| Depreciation & amortization | 1.65M | 1.65M | 392.00K | 362.00K | 368.00K | 364.00K |
| Free cash flow | -8.32M | -3.81M | 4.16M | 5.55M | 6.11M | 16.82M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 8.64M | -- | -- |
| Ending cash balance | 37.34M | 47.71M | 54.44M | 62.41M | 95.60M | 145.32M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -207.22 | -39.02 | -62.37 | -207.84 | 85.66 |
| ROA %i | -142.59 | -131.65 | -117.52 | -87.27 | -33.44 | -31.99 | -60.21 | 35.96 |
| ROIC %i | -- | -- | -- | -94.54 | -36.02 | -46.77 | -98.66 | 53.00 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | -84.62 |
| EBIT margin %i | -- | -140.43 | -42.93 | -28.43 | -401.55 | -162.22 | -350.62 | 88.90 |
| FCF / sales %i | -- | -- | -- | 36.08 | -- | -- | -- | -- |
| Current ratioi | 1.98 | 1.28 | 1.11 | 27.20 | 7.72 | 1.18 | 2.53 | 5.68 |
| Quick ratioi | 1.82 | 0.94 | 0.90 | 26.92 | 7.58 | 1.15 | 2.35 | 5.46 |
| Debt / assetsi | 306.77 | 756.90 | 629.38 | 1.21 | 12.24 | 25.40 | 33.85 | 22.20 |
| LT debt / equityi | -- | -- | -- | 0.97 | 18.16 | 8.93 | 150.95 | 40.60 |
| Interest coveragei | -6.99 | -2.77 | -0.80 | -21.66 | -125.36 | -29.68 | -11.26 | 11.87 |
| Revenue CAGR (3Y) %i | 0.00 | -- | -- | -- | -7.50 | 27.38 | -6.24 | 118.83 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -204.78 | 3.53 | 34.81 | 85.66 | 100.65 | 34.80 |
| ROA %i | -56.78 | 1.32 | 15.30 | 35.96 | 55.05 | 20.85 |
| ROIC %i | -88.40 | 4.62 | 22.94 | 53.00 | 78.82 | 27.34 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -164.53 | 48.18 | 73.31 | 88.90 | 115.40 | 55.12 |
| FCF / sales %i | -- | -- | -- | -- | 9.81 | 23.98 |
| Current ratioi | 3.02 | 7.85 | 8.62 | 5.68 | 4.89 | 5.17 |
| Quick ratioi | 2.79 | 7.66 | 8.29 | 5.46 | 4.74 | 5.02 |
| Debt / assetsi | 35.80 | 24.30 | 23.22 | 22.20 | 0.41 | 0.49 |
| LT debt / equityi | 149.30 | 52.68 | 46.77 | 40.60 | 0.36 | 0.40 |
| Interest coveragei | -7.78 | 3.52 | 7.52 | 11.87 | 18.28 | 13.13 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Research and development, manufacturing, commercialization and sale of innovative medicines and100.00%
Quote time 2026-10-08 09:19:14 · For reference only, not investment advice and not tailored to your situation.